FGFR4 and breast carcinoma: Molecular features that distinctly characterize the HER2E subtype in luminal disease were shown to be consistent with the HER2-enriched subtype in HER2-positive disease, including a putative epigenetic mechanism for FGFR4 expression in primary breast cancer tissue as well as in cell lines.